Predictive markers of tubulin-targeting agents in breast cancer

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 2, 2008, Pages

  Tang, Shou Ching ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

CYP3A4; Docetaxel; Epothilones; Ixabepilone; Microtubules

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPOTHILONE DERIVATIVE; ESTROGEN RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; IXABEPILONE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; TAXANE DERIVATIVE; TUBULIN; TUBULIN MODULATOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL; DRUG RESPONSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 52449098339     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.s.004     Document Type: Article

References (32)

1. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-34.
2. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407-14.
3. Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol 2007; 25(18 suppl):33s (Abstract 1006).
4. Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002; 20:2319-26.
5. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and resonse to chemotherapy. J Clin Pathol 2006; 59:729-35.
6. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005; 102:8315-20.
7. Sezgin C, Karabulut B, Uslu R, et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 2005; 17:96-103.
8. Warm M, Kates R, Mallmann P, et al. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. Anticancer Res 2007; 27:1031-8.
9. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006; 8:R66.
10. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96:1141-51.
11. Hayes D F, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-506.
12. Lüftner D, Henschke P, Flath B, et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly pacli-taxel in metastatic breast cancer. Anticancer Res 2004; 24:895-906.
13. Modi S, DiGiovanna M P, Lu Z, et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005; 23:483-7.
14. Hamilton A, Larsimont D, Paridaens R, et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 2000; 1:233-40; discussion 41-2.
15. Shalli K, Brown I, Heys SD, et al. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005; 19:1299-301.
16. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9:2992-7.
17. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16 (suppl 4):iv14-9.
18. Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer 2007; 120:2078-85.
19. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-asso-ciated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002; 3:341-5.
20. Hasegawa S, Miyoshi Y, Egawa C, et al. Mutational analysis of the class I β-tubulin gene in human breast cancer. Int J Cancer 2002; 101:46-51.
21. Andre F, Hatzis C, Anderson K, et al. Microtubule-associated protein- tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:2061-7.
22. Sève P, Reiman T, Lai R, et al. Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007; 60:27-34.
23. Barlow SB, Gonzalez-Garay ML, Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J Cell Sci 2002; 115:3469-78.
24. Fojo A T, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32(6 suppl 7):S3-8.
25. Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetexael by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 2001; 97:129-32.
26. Egawa C, Miyoshi Y, Takamura Y, et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001; 95:255-9.
27. Schmidt M, Bachhuber A, Victor A, et al. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003; 129:295-302.
28. Ding Z, Yang X, Pater A, Tang SC, et al. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. Biochem Biophys Res Commun 2000; 270:415-20.
29. Tang SC. BAG-1, an anti-apoptotic tumour marker. IUBMB Life 2002; 53:99-105.
30. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362:362-9.
31. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23:1169-77.
32. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23:422-31.